Key future directions will assess anti-androgens for secondary chemoprevention, as part of a combination approach with bladder-cancer-directed immunotherapies, and whether AR pathway and T-cell functional biomarkers can predict therapeutic outcomes. The gene discussed is AR; the disease is urinary bladder carcinoma.